Global WholeHealth Partners Corp (OTC: GWHP) Has Filed Applications to Sell Through WalMart, Amazon, Ebay and Soon Shopify
Global WholeHealth Partners
Corp is now funded for growth, sales, and expansion from EMC2
funding.
Global is presenting 5 OTC
(Over the Counter) products to be sold in the retail
marketplace.
San Clemente, CA -- July 29, 2021 -- InvestorsHub NewsWire
-- Global WholeHealth Partners Corp (OTC:
GWHP) through this agreement is funded for growth, sales,
and expansion. Per the terms of the EMC2 Purchase
Agreement, we may direct EMC2 to purchase up to $100,000,000 worth
of shares of our common stock under our agreement over a 36-month
period, generally in amounts up to 100,000 shares of our common
stock, which may be increased to up to 2,000,000 shares of our
common stock depending on the market price of our common stock at
the time of sale and subject to a maximum commitment by EMC2 of
$500,000 per regular purchase per day. The total amount of shares
to be sold through the EMC2 agreement is up to 8,578,177 shares of
common stock.
Global WholeHealth Partners Corp. (OTC:GWHP)
provides cutting edge technology using In-vitro Diagnostic (IVD)
Real-Time PCR Machines for detection of SARS-CoV-2 IgM/IgG
antibodies in human serum, plasma, or whole blood. It has led
the fight against vector borne terminal diseases such
as Ebola, ZIKA, Dengue, Malaria, Influenza and
Tuberculosis, Corona Viruses, and among other vector borne
diseases with an FDA Certificate of Exportability
(2260-11-2019). The company was founded on March 7, 2013
and is headquartered in San Clemente, CA.
GWHP develops, manufactures, and markets in vitro diagnostic
(IVD) tests for OTC, or consumer-use as well as professional rapid
diagnostic point-of-care (POC) test kits for hospitals, physicians’
offices, and medical clinics in the US and abroad. Currently, the
Company has 70 products FDA approved and many are approved for
OTC use, and 29 POC products approved by the FDA CLIA
WAIVED.
Call or email about special prices for this announcement
on all the tests.
Disclaimer:
The Company is not making any express or implied claims that its
product has the ability to eliminate, cure or contain the Covid-19
(or SARS-2 Coronavirus) at this time.
Media Contact:
Name: Charles Strongo,
CEO, Global WholeHealth Partners Corp.
Email: Sales@gwhpcorp.com Phone for
Sales: 877-568-4947
www.gwhpcorp.com
Forward-Looking Statements
This press release contains "forward-looking statements.”
Such statements may be preceded by the words "intends," "may,"
"will," "plans," "expects," "anticipates," "projects," "predicts,"
"estimates," "aims," "believes," "hopes," "potential" or similar
words. Forward-looking statements are not guarantees of future
performance, are based on certain assumptions and are subject to
various known and unknown risks and uncertainties, many of which
are beyond the Company's control, and cannot be predicted or
quantified and consequently, actual results may differ materially
from those expressed or implied by such forward-looking statements.
Such risks and uncertainties include, without limitation, risks and
uncertainties associated with (i) market acceptance of our existing
and new products, (ii) negative clinical trial results or lengthy
product delays in key markets, (iii) an inability to secure
regulatory approvals for the sale of our products, (iv) intense
competition in the medical device industry from much larger,
multinational companies, (v) product liability claims, (vi) product
malfunctions, (vii) our limited manufacturing capabilities and
reliance on subcontractors for assistance, (viii) insufficient or
inadequate reimbursement by governmental and other third party
payers for our products, (ix) our efforts to successfully obtain
and maintain intellectual property protection covering our
products, which may not be successful, (x) legislative or
regulatory reform of the healthcare system in both the U.S. and
foreign jurisdictions, (xi) our reliance on single suppliers for
certain product components, (xii) the fact that we will need to
raise additional capital to meet our business requirements in the
future and that such capital raising may be costly, dilutive or
difficult to obtain and (xiii) the fact that we conduct business in
multiple foreign jurisdictions, exposing us to foreign currency
exchange rate fluctuations, logistical and communications
challenges, burdens and costs of compliance with foreign laws and
political and economic instability in each jurisdiction. More
detailed information about the Company and the risk factors that
may affect the realization of forward-looking statements is set
forth in the Company's filings with the Securities and Exchange
Commission (SEC), including the Company's Annual Report on Form
10-K and its Quarterly Reports on Form 10-Q. Investors and security
holders are urged to read these documents free of charge on the
SEC's web site at http://www.sec.gov. The Company
assumes no obligation to publicly update or revise its
forward-looking statements as a result of new information, future
events or otherwise.
Global Wholehealth Partn... (CE) (USOTC:GWHP)
過去 株価チャート
から 11 2024 まで 12 2024
Global Wholehealth Partn... (CE) (USOTC:GWHP)
過去 株価チャート
から 12 2023 まで 12 2024